Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment approach consisting of dendritic cell (DC) vaccination to prime tumor-specific T cells, and a strategy to reprogram the desmo...

Full description

Saved in:
Bibliographic Details
Main Authors: Sjoerd H van der Burg, Thorbald van Hall, Heleen Vroman, Menno van Nimwegen, Christianne Groeneveldt, Priscilla Kinderman, Dana A M Mustafa, Nadine van Montfoort, Joachim Aerts, Melanie Lukkes, Sai Ping Lau, Casper H J van Eijck, Larissa Klaase, Mandy van Gulijk, Jasper Dumas, Sanne L A Lievense, Ralph Stadhouders, Yunlei Li, Andrew Stubbs, Koen A Marijt, Floris Dammeijer
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000772.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e000772.full

Similar Items